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Abstract
Background: Cytochrome P450 2B6 (CYP2B6) metabolizes efavirenz and nevirapine, the major core antiretroviral
drugs for HIV in Thailand. Rifampicin, a critical component of tuberculosis (TB) therapy is a potent inducer of CYP
enzyme activity. Polymorphisms of CYP2B6 and CYP3A4 are associated with altered activity of hepatic enzyme in
the liver and pharmacokinetics resulting in treatment efficacy. This study aimed to investigate whether CYP2B6 or
CYP3A4 polymorphisms had effects on plasma efavirenz and nevirapine concentrations when co-administered with
rifampicin in HIV/TB co-infected Thai adults.
Results: We studied 124 rifampicin recipients with concurrent HIV-1/TB coinfection, receiving efavirenz (600 mg/
day) (n = 65) or nevirapine (400 mg/day) (n = 59) based antiretroviral therapy (ART). The frequencies of GG, GT and
TT genotypes of CYP2B6-G516T were 38.46%, 47.69% and 13.85% in efavirenz group and 44.07%, 52.54% and 3.39%
in nevirapine group, respectively. The mean 12-hour post-dose plasma efavirenz concentration in patients with TT
genotype at weeks 6 and 12 of ART and 1 month after rifampicin discontinuation (10.97 ± 2.32, 13.62 ± 4.21 and
8.48 ± 1.30 mg/L, respectively) were significantly higher than those with GT (3.43 ± 0.29, 3.35 ± 0.27 and 3.21 ±
0.22 mg/L, respectively) (p < 0.0001) or GG genotypes (2.88 ± 0.33, 2.45 ± 0.26 and 2.08 ± 0.16 mg/L, respectively)
(p < 0.0001). Likewise, the mean 12-hour post-dose plasma nevirapine concentration in patients carrying TT
genotype at weeks 6 and 12 of ART and 1 month after rifampicin discontinuation (14.09 ± 9.49, 7.94 ± 2.76 and
9.44 ± 0.17 mg/L, respectively) tended to be higher than those carrying GT (5.65 ± 0.54, 5.58 ± 0.48 and 7.03 ±
0.64 mg/L, respectively) or GG genotypes (5.42 ± 0.48, 5.34 ± 0.50 and 6.43 ± 0.64 mg/L, respectively) (p = 0.003,
p = 0.409 and p = 0.448, respectively). Compared with the effects of CYP2B6-516TT genotype, we could observe
only small effects of rifampicin on plasma efavirenz and nevirapine levels. After 12 weeks of both drug regimens,
there was a trend towards higher percentage of patients with CYP2B6-TT genotype who achieved HIV-1 RNA
levels <50 copies/mL compared to those with GT or GG genotypes. This is the first report to demonstrate the
effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine concentrations when
co-administered with rifampicin in HIV/TB co-infected Thai adults.
Conclusions: CYP2B6-TT genotype had impact on plasma efavirenz and nevirapine concentrations, while rifampicin
co-administration had only small effects.
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Tuberculosis (TB) is the most common opportunistic
infections in human immunodeficiency virus (HIV)
infected individuals, accounting for more than 30% in
Thailand, and up to 50% of them die during treatment
[1]. The mortality is reduced in HIV-TB co-infected
patients who have started the combination antiretroviral
therapy after diagnosis of TB [2]. Concomitant adminis-
tration of highly active antiretroviral therapy (HAART)
and anti-TB medications is often complicated due to the
drug-drug interaction and the adverse effect profile. Efa-
virenz and nevirapine based HAART regimens have
mostly recommended to use as components of first-line
antiretroviral drug regimens worldwide [3]. As efavirenz
and nevirapine are potent non-nucleoside reverse tran-
scriptase inhibitors (NNRTIs), they are the preferable
option for initial antiretroviral treatments (ART) in
HIV/TB co-infection. Rifampicin is a critical component
of TB therapy while it is a potent inducer of cytochrome
P450 (CYP) enzyme activity [4]. The available pharma-
cokinetic data showed that rifampicin reduced the
plasma concentration of efavirenz and nevirapine of 13-
25% and 40%, respectively [5-7]. Recently, efavirenz was
shown in vitro to be primarily metabolized by hepatic
CYP2B6, with minor contributions from CYP3A4 and
CYP2A6 [4,8]. While rifampicin is an inducer of
CYP3A4, nevirapine induces more CYP2B6 than
CYP3A4 [9]. Nevirapine was also shown to be princi-
pally metabolized by CYP3A4 and CYP2B6 [10].
CYP2B6 and CYP3A4 genotypes are evidenced to be
associated with altered activity of hepatic enzyme in the
liver and pharmacokinetics that may influence efficacy
of treatment, since rifampicin causes decrease in efavir-
enz and nevirapine concentrations [11-13].
The CYP2B6 and CYP3A4 genes are highly poly-
morphic [14] and are subject to pronounce interindivi-
dual variability in expression and activity. A single
nucleotide polymorphism (SNP) at position 516 on the
CYP2B6 gene has been widely reported to play an
important role in the metabolism of antiretroviral drugs
[15-18]. This CYP2B6 genetic variant affects the efavir-
enz and nevirapine pharmacokinetics [16,19,20] and
associated with clinical response to nevirapine-contain-
ing regimens in children [16]. Significant advances have
led to a greater understanding of interactions between
genetic and host factors that influence the efficacy and
toxicity of efavirenz [19,21]. However, the findings from
one population may not be generalised to other popula-
tions due to the ethnic differences in drug effect and
body weight of the patients. In Thailand, it has been
recently reported that CYP2B6-G516T polymorphism
significantly affected the drug metabolism of efavirenz in
HIV-infected Thai children [22], while its impact on
nevirapine concentrations was less pronounced after
intra-partum single-dose nevirapine in HIV-infected
mothers [23]. As efavirenz or nevirapine-based HAART
is being used as the main therapy in Thailand, however,
limited information was obtained so far among various
Thai population regarding the influence of host genetic
polymorphism on these drug levels especially nevirapine
when co-administered with rifampicin which is essential
for optimization of ARV dosage or drug-drug interac-
tion. Therefore, the main objective of the present study
is to investigate whether CYP2B6 and CYP3A4 poly-
morphisms could influence the plasma efavirenz and
nevirapine levels when co-administered with rifampicin
in HIV/TB infected Thai adults. The evaluation of clini-
cal and immunological outcomes was also aimed.
Methods
Patients
One hundred and twenty four rifampicin recipients with
concurrent HIV-1/TB coinfection were studied. Sixty-
five of them received efavirenz (600 mg/day) based ART
while 59 received nevirapine (400 mg/day) based ART.
Initially, 142 patients were recruited for the study on a
randomized control trial to compare the efficacy of efa-
virenz and nevirapine among HIV-infected patients
receiving rifampicin at Bamrasnaradura Infectious Dis-
eases Institute (BIDI), Nonthaburi since December 2006
[24]. They are ARV naïve with active tuberculosis and
received rifampicin containing anti-TB regimens for 4-6
weeks prior to enrolment. The patients received oral
lamivudine (150 mg) and stavudine (30 mg for those
who weighed ≤ 60 kg and 40 mg for those who weighed
>60 kg) every 12 hours. They were randomized to
receive either efavirenz 600 mg at bedtime while fasting
or nevirapine 200 mg every 12 hours after 2 weeks at a
starting dose of 200 mg every 24 hours. The dosage of
rifampicin was 450 mg/day for patients who weighed ≤
50 kg and 600 mg/day for those who weighed >50 kg.
The anti-TB drug regimen was isoniazid, rifampicin,
ethambutol and pyrazinamide for the first two months,
followed by isoniazid and rifampicin for the subsequent
4-7 months. Among 142 patients recruited, 25 patients
(9 in the efavirenz group and 16 in the nevirapine
group) failed to continue the study because of hepatitis
(2 cases in the nevirapine group), skin rash (3 in the efa-
virenz group and 2 in the nevirapine group), death (2 in
the efavirenz group and 6 in the nevirapine group),
transfer to the other hospital (1 in the nevirapine
group), or lost to follow up (4 in the efavirenz group
and 5 in the nevirapine group). In the present study, we
analyzed 124 patients who have a complete data set of
plasma drug levels at week 6 and 12 of ART and 1
month after rifampicin discontinuation. The study was
approved by Institutional Ethics Committees of Bamras-
naradura Infectious Diseases Institute and the Ministry
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consents were obtained from all participants.
Blood samples
EDTA bloods were collected from patients for SNP gen-
otyping, CD4 T cell counts and HIV-1 viral load.
Lithium heparinized bloods were collected after 12
hours of drug administration (C12)a tw e e k s6a n d1 2o f
ART and after rifampicin discontinuation for 1 month
for analysis of plasma efavirenz and nevirapine concen-
trations. The plasma were separated by centrifugation at
1800 g for 20 minutes and stored at -20°C.
SNP genotyping of CYP2B6 and CYP3A4
The genomic DNA was extracted by using QIAamp
DNA blood Mini kit (QIAGEN, Hilden, Germany) and
stored at -20°C for SNP genotyping. Genotyping of alle-
lic variants in CYP2B6 and CYP3A4 were carried out by
real-time PCR using the allelic-specific fluorogenic 5’
nuclease chain reaction assay by ABI PRISM 7500
sequence detection system (Applied Biosystems, Foster
City, CA) as described previously [15]. Seven SNPs were
genotyped: 4 SNPs of CYP2B6-G516T, -C777A, -A415G
and -C1459T and 3 SNPs of CYP3A4-T566C, -T878C
and C1088T. Each 25 μlP C Rm i x t u r ec o n t a i n e d2 0n g
of genomic DNA, 900 nM primers, 200 nM TaqMan
minor groove binder (MGB) probes and 12.5 μl TaqMan
universal PCR master mix. The thermal cycler program
was set up at 95°C for 10 minutes, and then repeated 40
cycles with 95°C for 15 seconds and 60°C for 1 minute.
The plate was read by the allelic discrimination settings.
The SNP assay was set up using SDS, version 1.3.0 as
an absolute quantification assay. Post-assay analysis was
done by using SDS software.
Determination of plasma efavirenz and nevirapine
concentration
Plasma efavirenz and nevirapine concentrations were
measured by reverse phase high performance liquid
chromatography (HPLC) method at the HIV-Nether-
lands-Australia-Thailand (HIV-NAT) Research Pharma-
cokinetic Laboratory, Chulalongkorn Medical Research
Center (Bangkok, Thailand). HPLC was performed in
accordance with the protocol developed by Department
of Clinical Pharmacology, University Medical Center
Nijmegan (Nijmegan, the Netherlands) [25].
CD4 T lymphocyte counts and plasma HIV-1 RNA
quantitation
The CD4 T lymphocyte counts were done at baseline
and every 12 weeks after initiation of antiretroviral treat-
ment by flow cytometry using monoclonal antibodies
with three colors reagent (TriTEST, Becton Dickinson
BioSciences, USA) and analyzed by FACScan flow
cytometer (Becton Dickinson BioSciences, USA.). Plasma
HIV-1 RNA was determined by RT-PCR at baseline and
every 12 weeks after initiation of ART and quantified
using the COBAS Amplicor, version 1.5 (Roche Diag-
nostics, USA). The lower detection limit for HIV-1 RNA
level is 50 copies/mL.
Statistical analysis
The different genotypes in relation to plasma drug levels
were analysed by SPSS software version 14.0 (ID
5038562) (SPSS Inc., Chicago, IL, USA). If unpaired
one-way analysis of variance (ANOVA) was significant
(p < 0.05), then post hoc Scheffe’s F test was applied for
multiple comparison. When plasma drug levels of differ-
ent time points were compared, paired T test was used.
The CD4 T cell counts and HIV-1 viral load in patients
carrying different genotypes were compared by Kruskal-
Wallis test. A difference in proportion of patients who
achieved plasma HIV-1 RNA < 50 copies/ml at week 12
of ART was evaluated by Chi square or Fisher’se x a c t
test. A p value of < 0.05 was considered statistically
significant.
Results
Patient characteristics
The baseline characteristics of patients are shown in
Table 1. All 124 patients were ethnically Thai and
among these, 64.6% and 67.8% were male in efavirenz
and nevirapine groups, respectively. The patients had
the mean ages of 35.89 ± 8.17 and 38.03 ± 8.60 years
and the mean body weights of 53.30 ± 9.79 and 54.39 ±
9.39 kg in efavirenz and nevirapine groups, respectively.
Similar levels of laboratory parameters including alkaline
phosphatase, aspartate aminotransferase, alanine amino-
transferase, total bilirubin and direct bilirubin were seen
in both patient groups. However, the levels of alkaline
phosphatase among patients carrying TT genotype in
efavirenz group were higher than those carrying GG or
GT genotypes, but this difference was not statistically
significant (p = 0.085). The median (interquartile range,
IQR) CD4 T lymphocyte counts were similar in both
groups. In nevirapine treatment group, the log number
of plasma HIV-1 viral load among patients carrying GG,
GT and TT genotypes seem to be significantly different
(p = 0.041).
Frequencies of CYP2B6 and CYP3A4 genetic
polymorphisms
Seven SNPs: 4 SNPs of CYP2B6- G516T, -C777A,
-A415G and -C1459T and 3 SNPs of CYP3A4-T566C,
-T878C and -C1088T were genotyped. For CYP2B6-
G516T, 38.46% (25/65) of GG genotype (wild-type),
47.69% (31/65) of GT genotype (heterozygous mutant)
and 13.85% (9/65) of TT genotype (homozygous
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while in nevirapine group, there were 44.07% (26/59) of
CYP2B6-516GG genotype, 52.54% (31/59) of GT geno-
type and 3.39% (2/59) of TT genotype. The genotype
frequencies of CYP2B6-C777A and -A415G in efavirenz
and nevirapine groups were 100% of homozygous
mutant AA and 100% of homozygous wild-type AA,
respectively. For CYP2B6-C1459T, there were 98.5%
(64/65) of CC homozygous wild-type and 1.5% (1/65) of
CT heterozygous mutant in efavirenz group, and 91.5%
(54/59) of CC homozygous wild-type, 6.8% (4/59) of CT
heterozygous mutant and 1.7% (1/59) homozygous
mutant in nevirapine group. Likewise, the genotype fre-
quencies in CYP3A4-T566C and -C1088T were 100% of
homozygous wild-type TT and homozygous mutant TT,
respectively, in both efavirenz and nevirapine groups.
For CYP3A4-T878C, there were 95.4% (62/65) of homo-
zygous TT and 4.6% (3/65) of heterozygous TC, and
98.3% (58/59) of homozygous TT and 1.69% (1/59) of
heterozygous TC in efavirenz and nevirapine groups,
respectively.
CYP2B6-G516T and CYP3A4-T878C genetic polymorphisms
and plasma efavirenz and nevirapine concentrations
Among 4 SNPs of CYP2B6-G516T, -C777A, -A415G
and -C1459T being evaluated, the frequencies of wild-
type, heterozygous mutant and homozygous mutant
were well distributed only in CYP2B6-G516T
polymorphism, therefore, the analysis of this gene poly-
morphism was further done in relation to plasma efavir-
enz and nevirapine levels. The mean plasma efavirenz
concentration in patients with homozygous TT genotype
at weeks 6 and 12 of ART and 1 month after rifampicin
discontinuation (10.97 ± 2.32, 13.62 ± 4.21 mg/L and
8.48 ± 1.30 mg/L, respectively) were significantly higher
than those with GT genotype (3.43 ± 0.29, 3.35 ± 0.27
mg/L and 3.21 ± 0.22 mg/L, respectively) or GG geno-
type (2.88 ± 0.33, 2.45 ± 0.26 and 2.08 ± 0.16 mg/L,
respectively) (p < 0.0001) (F i g u r e1 a ,b ,c ) .S i m i l a r
results were found in nevirapine group (Figure 1d, e, f)
in that the mean plasma drug concentration of patients
with TT genotype at weeks 6 and 12 of ART and 1
month after rifampicin discontinuation (14.09 ± 9.49,
7.94 ± 2.76 and 9.44 ± 0.17 mg/L, respectively) tended
to be higher than those with GT genotype (5.65 ± 0.54,
5.58 ± 0.48 and 7.03 ± 0.64 mg/L, respectively) or GG
genotype (5.42 ± 0.48, 5.34 ± 0.50 and 6.43 ± 0.64 mg/
L, respectively) (p = 0.003, p = 0.409 and p = 0.448,
respectively).
One month after rifampicin discontinuation, there was
a clear trend towards lower plasma efavirenz levels than
those during concomitant rifampicin at week 6 and 12
of ART regardless of CYP2B6 G516T genotypes. In fact,
when we evaluated effects of rifampicin on plasma efa-
virenz levels without stratifying CYP2B6 G516T poly-
morphisms, the plasma efavirenz levels after rifampicin
Table 1 Baseline characteristics of 124 HIV/TB co-infected patients with CYP2B6-G516T genotypes in efavirenz and
nevirapine groups.
Baseline characteristics Efavirenz group (n = 65) Nevirapine group (n = 59)
CYP2B6-G516T CYP2B6-G516T
GG GT TT p-value GG GT TT p-value
n=2 5 n=3 1 n=9 n=2 6 n=3 1 n=2
Sex Male: Female 16: 9 21: 10 5: 4 0.795 17: 9 22: 9 1: 1 0.707
Age
years, mean (SD)
36.48
(8.08)
35.68
(8.82)
35
(6.63)
0.882 36.48
(8.08)
35.68
(8.82)
35
(6.63)
0.467
Body weight
kg, mean (SD)
52.9
(1.87)
53.94
(1.89)
52.22
(3.04)
0.872 54.62
(2.06)
54.7
(1.52)
46.5
(6.5)
0.489
Alkaline phosphatase,
U/L, mean (SD)
149.2
(18.38)
137.1
(16.91)
233.9
(68.45)
0.085 150.25
(28.9)
113.97
(11.1)
125
(4)
0.458
Aspartate aminotransferase U/L, mean (SD) 32.8
(2.35)
40.48
(3.32)
43.22
(10.21)
0.202 48.54
(7.31)
35.58
(2.99)
26
(1)
0.167
Alanine aminotransferase, U/L, mean (SD) 27.0
(3.05)
28.55
(2.89)
31.22
(8.89)
0.821 29.81
(3.95)
27.94
(3.57)
23.5
(5.5)
0.877
Total bilirubin,
mg/dL, mean (SD)
4.9
(4.34)
0.56
(0.55)
0.43
(0.07)
0.452 2.97
(2.4)
1.13
(0.57)
0.6
(0.1)
0.703
Direct bilirubin,
mg/dL, mean (SD)
0.45
(0.14)
0.37
(0.12)
0.21
(0.05)
0.631 0.28
(0.047)
0.52
(0.199)
0.30
(0.1)
0.568
CD4 count,
cells/μl, median (IQR)
41
(18-102)
54
(24-120)
67
(12.5-168)
0.818 35.5
(23.5-97)
45
(25-113)
30.5
(23)
0.595
Log Plasma HIV-1 viral load
median (IQR)
5.90
(5.57-6.0)
5.93
(5.39-6.0)
5.64
(5.50-6.0)
0.729 5.86
(5.46-6.0)
5.60
(5.41-5.81)
5.80
(Q1 = 5.59)
0.041*
* Statistically significant by Kruskal-Wallis test. SD: standard deviation. IQR: interquartile range.
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lower than those at week 6 (4.26 ± 3.96 mg/L) (p =
0.043) and tended to be lower than those at week 12
(4.42 ± 5.97 mg/L) (p = 0.133). In contrast, plasma
nevirapine levels at 1 month after rifampicin disconti-
nuation (6.84 ± 3.4 mg/L) were significantly higher than
those at week 6 (5.83 ± 3.6 mg/L, p = 0.034) and those
at week 12 (5.56 ± 2.63 mg/L, p < 0.001). The reason
for these discrepant results on effects of rifampicin on
plasma efavirenz and nevirapine levels is not clear at
present. Further studies including evaluation of plasma
drug levels at time points other than 12-hour post-dose
would be thus necessary. Nevertheless, we at least can
conclude that the magnitude of effects on plasma
Figure 1 Mean plasma efavirenz and nevirapine concentratio n si nH I V / T Ba d u l t sw i t hd i f f e r e n tg e n o t y p e so fCYP2B6-G516T
polymorphism. The scatter diagram of plasma efavirenz (Fig.1a, b, c) and nevirapine distribution (Fig. 1d, e, f) at weeks 6 and 12 of ART and 1
month after rifampicin discontinuation. The numbers of GG, GT and TT genotype patients were 25, 31 and 9 in efavirenz group and 26, 31, 2 in
nevirapine group.
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smaller than that by CYP2B6 516 TT genotype.
With respect to CYP3A4, the analysis was done in
only CYP3A4-T878C, since there was no variation at the
CYP3A4-T878C and -C1088T in our study subjects. The
results showed that the mean plasma efavirenz concen-
tration at weeks 6 and 12 of ART and 1 month after
rifampicin discontinuation were 4.00 ± 0.42, 4.20 ± 0.72
and 3.48 ± 0.34 mg/L, respectively, in patients with
homozygous TT genotype and 9.62 ± 6.35, 8.97 ± 6.33
and 3.87 ± 1.69 mg/L, respectively, in those with hetero-
zygous TC genotype. Similarly, the mean plasma nevira-
pine concentration at weeks 6 and 12 of ART and 1
month after rifampicin discontinuation were 5.85 ± 0.48,
5.50 ± 0.34 and 6.80 ± 0.45 mg/L, respectively, in
patients with homozygous TT genotype, and 4.8, 8.69
and 9.12 mg/L, respectively, in one patient with hetero-
zygous mutant TC genotype. Although there was a
trend towards higher plasma drug levels in patients with
heterozygous mutant TC genotype, appropriate statisti-
cal evaluation of this difference was difficult due to
small numbers of heterozygous mutant TC.
CD4 T cell counts and HIV-1 viral load among patients
with CYP2B6-G516T genotypes
The CD4 T cell counts among patients carrying differ-
ent CYP2B6 genotypes in efavirenz and nevirapine
groups are shown in Figure 2. The number of CD4 T
cells in patients with TT, GT and GG genotypes
increased in a similar manner at all time points at weeks
12, 24, 36 and 48 of ART compared to the baseline in
both efavirenz and nevirapine groups. No significant dif-
ference in median CD4 T cell counts of each genotype
at different time points was seen in efavirenz group (p =
0.818, 0.838, 0.783, 0.753 and 0.587 for baseline, weeks
12, 24, 36 and 48 of ART, respectively), whereas, in
nevirapine group, the median CD4 T cell counts of
patients with TT genotype seem to be lower than those
with the other two genotypes at different time points,
although this difference did not reach statistical signifi-
cance (p = 0.595, 0.182, 0.554, 0.573 and 0.494, respec-
tively) (Figure 2a, b).
As shown in Table 2, when the proportion of patients
with HIV-1 RNA level <50 copies/mL (log 1.69) were
compared among CYP2B6-G516T genotypes at week 12
of ART, 88.89% (8/9) of patients with TT genotype in
efavirenz group could achieve the HIV-1 RNA levels
<50 copies/mL, which were higher than those with GT
genotype (77.42%, 24/31) and GG genotype (68%, 17/
25), although this difference was not statistically signifi-
cant (p = 0.430). Similarly, in nevirapine group, 100%
(2/2) of those with TT genotype, 70.97% (23/31) of
those with GT genotype and 60% (15/26) of those with
GG genotype could achieve the HIV-1 RNA levels <50
copies/mL, but this difference also did not reach statisti-
cal significance (p = 0.288) due to small numbers of
patients with homozygous TT genotype in this study. At
weeks 24, 36 and 48 of ART, nearly all the patients
achieved undetectable viral load, since viral load were
not detected in 95.38% (62/65), 93.65% (59/63) and
87.9% (54/62), respectively, of efavirenz group and
96.55% (56/58), 94.64% (53/56) and 94.64% (53/56),
respectively, of nevirapine group.
Discussion
This is the first report to demonstrate the effects of
CYP2B6-G516T and CYP3A4-T878C polymorphisms on
plasma efavirenz and nevirapine concentrations in
rifampicin-treated HIV/TB co-infected Thai adults. The
results indicated that the wide interindividual variability
of efavirenz concentrationsi ss t r o n g l yi n f l u e n c e db y
CYP2B6-516TT genotype by the finding of significantly
higher plasma efavirenz concentration at weeks 6 and
12 of ART and 1 month after rifampicin discontinuation
compared to those with GT or GG genotype. Likewise,
it seems to be that this CYP2B6-516TT would also
influence nevirapine concentrations, although it was less
pronounced probably due to the small samples size of
homozygous mutant TT in our sample set. The present
results were in line with the previous report on efavirenz
pharmacokinetics when co-administration with rifampi-
cin in HIV/TB co-infected Indian [26,27] and Ghana
patients [28] in that plasma efavirenz was highest in
patients with CYP2B6-516TT genotype when compared
to those with GT or GG genotypes. While the heterozy-
gous TC mutant in CYP3A4-T878C in this study seems
to have some effects on plasma drug concentrations in
patients at weeks 6 and 12 of ART and 1 month after
rifampicin discontinuation in both efavirenz and nevira-
pine groups, further statistical analysis was not done
due to the relatively less variation of CYP3A4 among
Thai adults in this study. Further investigation should
include a larger sample size with varying genotypes in
order to draw a definite conclusion on the effect of
CYP3A4 variations.
In this study, the frequency of CYP2B6-G516T among
124 Thai adults was 8.9%, which was close to that of
our recent study on 237 HIV-infected Thai adults with
different rate of CD4 T cell recovery after ARV treat-
ment (9.7%) (submitted for publication) and slightly
lower than what has been reported in Thai children
(11%) [22]. Comparing to the other ethnic groups, it
was higher than those of Japanese (3.3%) [15] and Cau-
casian (6%) [14], but lower than that of African-Ameri-
can (20%) [21] or African population (23%) [28,29].
Although the frequencies of CYP2B6-G516T were differ-
ent among populations or ethnicity, the pharmacoge-
netic studies reported so far in HIV patients
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ciated with plasma efavirenz concentration
[15,19,21,29,30]. The findings of CYP2B6 516TT geno-
type in the present study support its effect on plasma
efavirenz concentration in different ethnic group and
gave additional information of this SNP on nevirapine
based-ART when co-administered with rifampicin. The
recent pharmacogenetic study in HIV patients co-admi-
nistrated with efavirenz and rifampicin demonstrated
that patients carrying TT genotype had significantly
higher mean plasma efavirenz but lower oral clearance
[28], indicating that rifampicin does not fully reverse the
poor metabolizer phenotype and that TT genotype can
be used to identify poor metabolizers of efavirenz even
Figure 2 Median CD4 T cell counts among HIV/TB adults with CYP2B6-G516T polymorphism at different time points. (Black diamond)
GG genotype, (Black square), GT genotype, (Black triangle) TT genotype in efavirenz (a) and nevirapine groups (b) at baseline, 12, 24, 36 and 48
weeks of ART.
Table 2 Number of patients with plasma HIV-1 RNA < 50 copies/ml at week 12 of ART.
Efavirenz group (N = 65) Nevirapine group (N = 59)
CYP2B6-G516T CYP2B6-G516T
GG
n=2 5
GT
n=3 1
TT
n=9
p-value* GG
n=2 6
GT
n=3 1
TT
n=2
p-value**
No. of patients
(%)
17
(68)
24
(77.42)
8
(88.89)
0.430 15
(60)
23
(70.97)
2
(100)
0.288
* Chi-square test
** Fisher’s exact test
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tently, the present results also indicated that rifampicin
coadministration in HIV/TB infected patients did not
significantly alter plasma efavirenz and nevirapine levels
in patients with TT genotype (p > 0.05). Other possible
factors that might affect the plasma drug levels could be
excluded since they were carefully controlled.
Although rifampicin can cause the decrease in NNRTI
concentrations, the mean plasma efavirenz and nevira-
pine concentrations in all studied patients with TT, GT
and GG genotypes had plasma drug levels above the
minimum recommendation (1 mg/L for efavirenz and
3.4 mg/L for nevirapine). One important conclusion
from our recent prospective and randomized clinical
trial in patients with concurrent HIV/TB receiving
rifampicin [24] is that the standard dosage of efavirenz
600 mg or nevirapine 400 mg per day and co-adminis-
tration with rifampicin was adequate for HIV-1 suppres-
sion, however, variation in the plasma drug levels in
some patients were found, which might be due to the
genetic variations among individuals. Although we
reported recently that high body weights of the patients
were associated with a low efavirenz C12 at weeks 6 and
12 of ART [31], the present results demonstrated that
the body weights did not differ among patients with dif-
ferent genotypes of CYP2B6 G516T polymorphism. The
present results thus demonstrated that rifampicin has
very small effects on efavirenz and nevirapine plasma
drug. The advantage of our present study over previous
studies is that plasma efavirenz and nevirapine concen-
trations during co-administration of rifampicin could be
compared with those without rifampicin after complet-
ing TB drug treatment.
In general, the high plasma efavirenz and nevirapine
levels could lead to the adverse effect such as rash,
hepatitis, and neuropsychological toxicity [32,33]. In
order to reduce such adverse effects, several studies
attempted to test the feasibility of genotype-based dose
reduction of efavirenz in African-American [34] and
Japanese HIV infected patients [35] and showed that
efavirenz dose reduction is feasible and can reduce efa-
virenz-associated central nervous system symptoms in
homozygotes of CYP2B6-G516T. Although patients with
CYP2B6-516TT in our cohort had obviously high
plasma efavirenz levels at all time points and certain
degree of central nervous system and psychiatric mani-
festations, they were all well tolerated with the adverse
effects. The adverse drug events have not recorded in
nevirapine based treatment probably due to the limited
number of patients with homozygous TT. Since there
were 7 cases who could not complete the study due to
side effects [24] it is necessary to determine CYP2B6
G516T genotypes of these individuals in order to know
whether CYP2B6-516TT homozygote in Thailand were
all well tolerated with the adverse effects of efavirenz
and nevirapine.
With respect to possible correlation of the variations
in plasma efavirenz and nevirapine levels with the treat-
ment outcome, our results indicated that the patients
with CYP2B6 516TT genotype had a higher frequency
of viral load suppression at week 12 of ART than those
with GT and GG genotype. The CD4 T cell counts
increased after treatment at all time points which were
correlated with HIV-1 viral load reduction. When the
effect of different CYP2B6-G516T genotypes was ana-
lysed, no difference was observed among patients with
TT, GT and GG genotypes in both efavirenz and nevira-
pine groups. Collectively, it i si n d i c a t e dt h a tt h ee f a v i r -
enz and nevirapine-based ART co-administered with
rifampicin are well correlated with virological and
immunological outcomes in patients undergoing treat-
ment for HIV and TB.
In summary, the CYP2B6 and CYP3A4 polymorphisms
were analysed, for the first time, in HIV/TB co-infected
Thai adults receiving efavirenz and nevirapine based-
ART co-administered with rifampicin and the results
indicated that only 516G>T in CYP2B6 gene, but not
CYP3A4 gene polymorphism, gave the significant effects
on plasma drug levels. Only small effects of rifampicin
on efavirenz and nevirapine plasma concentration were
observed. However, for further investigation, other SNPs
such as CYP2B6 T 9 8 3 Co rT G A T C - CYP2B6 haplotypes
which were shown to influence the NNRTI plasma drug
levels [23,36,37] should be taken into account and larger
sample size with varying genotypes should be included.
Conclusions
CYP2B6-TT genotype had effects on both the plasma
efavirenz and nevirapine concentrations in HIV/TB
patients when co-administered with rifampicin. The
information might be useful for better treatment of
patients with HIV or HIV/TB.
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